Articles Referencing BBH

Zacks.com

Biotechnology ETF Investing 101 - ETF News And Commentary

With ever-increasing health care spending and insatiable demand for new drugs, the biotechnology sector looks poised for good growth going forward. Furthermore, the U.S. biotech... Read >>

Benzinga

S&P Highlights Biotech ETFs

Bolstered by an accommodating Food & Drug Administration and promising recent clinical results for drugs aimed at treating conditions such as hepatitis C and multiple... Read >>

Benzinga

Three Sector ETFs Up 20% or More YTD

The S&P 500 continued its flirtation with the psychologically important 1,600 level Thursday with a gain of almost one percent. Including dividends paid, the benchmark U.S. index is up... Read >>

Zacks.com

Is the Biotech Sector Still a Market Leader? - Real Time Insight

The biotechnology sector has been a strong performer for much of 2013. The space has seen huge gains over and above that of the broad market, with biotech benchmarks outpacing the S&P... Read >>

Benzinga

Biotech Mutual Funds Show ETFs Are The Place to Be

In March, we compared a a popular energy sector ETF and a comparable mutual fund with the idea being to figure out when relevant factors are considered, which vehicle is best for investors. ... Read >>

Benzinga

A Look Ahead: This Week's ETFs to Watch

Market participants cannot look back on the dour performance turned in by U.S. stocks last week. The one where the S&P 500 slumped 2.1 percent and turned not only its worst... Read >>

Benzinga

Vertex News Lifts Biotech ETFs

Shares of biotechnology firm Vertex Pharmaceuticals (NASDAQ: VRTX ) are soaring by more than 55 percent early Friday and have touched a new all-time high after the company announced late... Read >>

Benzinga

Under The Hood: An Unheralded Biotech ETF

Another day, another set of fresh all-time highs for the major biotechnology ETFs . Biotech investors were treated to the same feat in late March , but as health care has continued to be a... Read >>

Benzinga

Biotech Breakout Boosting ETFs

The four horsemen of the biotechnology - Amgen (NASDAQ: AMGN ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ) and Gilead Sciences (NASDAQ: GILD ) - all hit new 52-week highs... Read >>

Benzinga

Exploring No Man's Land ETFs

First, the phrase "no man's land ETFs " needs to be defined and explained. To be sure, it is not as negative as some might be thinking. Actually, it is not negative at all.... Read >>

Zacks.com

Gilead Puts Biotech ETFs in Focus - ETF News And Commentary

California-based Gilead Sciences ( GILD ) was in focus last week as it saw some encouraging clinical trial data on its HIV pill-TAF. This report pushed up GILD by about 4.5% last week and... Read >>

Investor's Business Daily

5 ETFs With Strong Bullish Trends: Ned Davis

The best ETF investments at the moment are biotechs and international bonds, according to the Ned Davis Research Group of Venice, Fla. In an "ETF Highlights" report sent Tuesday,... Read >>

Investor's Business Daily

Gilead Sciences And Celgene Liven Up Biotech ETFs

Positive clinical trial results fromGilead Sciences ( GILD ) andCelgene ( CELG ) released over the weekend lifted biotechnology ETFs to their biggest one-day gains in as many as three... Read >>

Benzinga

Investors Cheating Themselves by Focusing on Largest ETFs

In the ETF game, size matters. As the exchange-traded products industry has evolved, professional and retail investors alike have become more obsessed with numbers. Underscoring the notion that... Read >>

Benzinga

Argument For Low Volume ETFs Gains Steam

It has been duly noted that ETF trading and investing is a numbers game. To that end, many experts treat this numbers game the way they would drafting a fantasy football league. That is to say ... Read >>

Displaying 1-15 of 23
<< first < previous 1 2 next > last >>